Soligenix, Inc. — Q2 2013 Form 10-Q
Reporting period: Three and six months ended June 30, 2013; filing signed August 12, 2013. Soligenix is a clinical-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Revenue is principally from NIH grants, rather than product sales.
Financial performance
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Revenue | $632,278 | $762,851 | $1,532,632 | $1,410,269 |
| Gross profit | $104,330 | $146,521 | $261,027 | $237,368 |
| Gross margin | 16.5% | 19.2% | 17.0% | 16.8% |
| Operating expenses | $2,860,214 | $1,128,198 | $4,104,808 | $2,660,035 |
| Operating loss | $(2,755,884) | $(981,677) | $(3,843,781) | $(2,422,667) |
| Net loss | $(3,405,157) | $(979,878) | $(4,492,571) | $(2,418,633) |
| Basic and diluted loss per share | $(0.28) | $(0.09) | $(0.38) | $(0.22) |
- Six-month operating cash use was $1.45 million, versus $1.56 million in 2012. Investing cash use was $6,014. Financing provided $6.22 million, primarily from the public offering. Cash rose to $8.13 million from $3.36 million at year-end 2012.
- At June 30, current assets were $8.51 million and current liabilities $6.82 million, including a $5.18 million warrant liability. The company reported working capital of $6.87 million excluding that noncash warrant liability. No interest-bearing debt is identified in the supplied filing text.
- Total assets were $9.27 million; shareholders’ equity was $2.45 million. The filing reports $1.36 million in accounts payable and $276,613 in accrued compensation.
Material changes and unusual items
- Q2 revenue declined 17% year over year; six-month revenue increased 9%. Management attributed fluctuations to the timing of grant activity and related development work.
- R&D expense rose to $2.14 million in Q2 from $501,000, and to $2.90 million for six months from $1.38 million. Management cited a $1.5 million stock issuance to Intrexon under an exclusive collaboration and costs associated with the pediatric Crohn’s Phase 1/2 trial.
- The six-month net loss increased 86% year over year. It includes a $649,576 noncash charge from remeasurement of offering-related warrants, classified as a liability because of down-round and net-settlement provisions.
- In June, the company sold 6,773,995 shares in a registered unit offering, with five-year warrants for 5,080,500 shares at $1.65 per share. Net proceeds were $6,216,762. It also issued 1,034,483 shares to Intrexon, and shares to vendors and option holders. Common shares outstanding were 19,030,487 as of August 7, 2013.
Outlook, risks and contingencies
- Management expected cash to fund working capital and capital expenditures into the first quarter of 2015, based on cash, grant proceeds and expected New Jersey tax-credit-transfer proceeds. This is an estimate, not a guarantee; the company may seek further equity financing and stated there is no assurance it can obtain financing on favorable terms.
- Approximately $2.3 million of active grant funding remained available through 2014. Management planned additional grant applications and forecast approximately $5.8 million of R&D spending over the next 12 months before grant reimbursements, offset by approximately $2.0 million of grant revenue.
- Planned development included Phase 2 SGX942 and Phase 2/3 SGX203 trials in the second half of 2013; Phase 2 orBec in the second half of 2013; and Phase 2 SGX201 and RiVax in the first half of 2014. These are plans disclosed at the filing date, not assurances of execution or results.
- Soligenix had submitted a BARDA contract proposal for OrbeShield and expected a response in the second half of 2013. Development and potential government procurement depend on clinical, regulatory, funding and contracting outcomes.
- Commitments included approximately $362,500 under licensing agreements, potentially payable upon milestones, and $179,000 in future property and other lease obligations; total disclosed obligations over five years were $541,500. Management identified typical biotechnology risks, including clinical development, FDA regulation, funding, intellectual property and product liability. No additional risk factors were reported beyond those in the 2012 Form 10-K.
Key facts for investors to verify
- Cash runway assumptions and the timing and availability of grants and New Jersey tax-credit-transfer proceeds.
- Share dilution and warrant terms, including liability remeasurement effects and the potential exercise of outstanding warrants.
- Whether planned clinical trials proceed on schedule and whether reported early-stage safety or preclinical findings translate into later-stage efficacy.
- Outcome of the BARDA proposal and continued grant funding, particularly given grant-dependent revenue and development plans.
- Actual R&D spending, cash burn and financing needs compared with management’s forecasts.